CClinicalTrials.gg
Status unknownNCT05733871Updated Feb 17, 2023

Evaluation of the Effectiveness of Standard and Innovative Products That Represent a Substitute Meal for Weight Management in a Reduction Diet

An interventional study of meal replacement product- STANDARD PRODUCT and Meal replacement product- INNOVATIVE PRODUCT in Overweight and Obesity and Body Weight, sponsored by Children's Hospital Srebrnjak. Status unknown at 1 site in Croatia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-02-17.

Sponsored by Children's Hospital Srebrnjak · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Randomized stratified controlled clinical study for evaluate the effectiveness of a diet program designed for reduce body weight through standard and innovative products that are a substitute meal for weight management in a reduction diet.

Read the detailed description

In the last few decades, there has been an increase in the number of obese people to the level of a global epidemic as a result of inadequate diet, sedentary lifestyle, but also genetic predispositions. The World Health Organization (WHO) declared obesity to be the biggest, global, chronic health problem in adults, that is increasingly becoming a more serious problem than malnutrition.On the other hand, obesity is a risk factor for the development of contemporary non-infectious diseases today that account for more than 80% of mortality in developed countries, such as vascular disease, diabetes and respiratory diseases such as asthma.

This trend is also recorded in Croatia, both in adult population and in children if the data from 2003 and 2015 are being compared, while according to data from 2019, almost two thirds of the adult population in Croatia were overweight or obese (42% overweight, 23% obese).

In cooperation with Podravka, Belupo has developed a standard and innovative product line. Products are replacing one or more one or more daily meals, and thay must comply with Regulation 2016/1413 requirements related to energy value, content and composition of fats and proteins, the amount of vitamins and minerals in this type of products.

The standard product line contains common ingredients and this type of product already exists on world markets, while the innovative product line differs from the standard one by implementing raw materials that are considered better sources of potentially bioactive components.

The study for a group of adult participants was designed in such a way that the participants in the initial stage follow a low-calorie diet of about 1000 - 1100 kcal, whereby 5 daily meals are replaced with meal replacements in the reduction diet (active group and active control) (intensive stage). In subsequent stages, subjects gradually increase their energy intake and gradually substitute meal replacement product (MRP) with regular nutritionally profiled meals (active stage and maintenance stage). The final (stable) stage represents the stage in which, in addition to one meal replacement per day, the usual meals designed by the nutritionists of Belupo and the Culinary Center of Podravka are consumed, where education and nutrition counseling is also carried out.

Study entry stage (0-2 weeks): subjects are recruited respecting the inclusion and exclusion criteria. Recruitment is carried out by a doctor. During this stage, subjects replace standard meals with meal replacement products and reduce energy intake to a final defined intake depending on the group of subjects.

36 participants in a ratio of 1:1:1

  • active group - 12
  • active control (positive control group) - 12
  • control group (negative control group) - 12

The daily energy intake is defined at around 1000-1100 kcal per day, and counseling on nutrition and physical activity is carried out.

  1. Intensive stage (2-14 weeks) about 1000 - 1100 kcal/day 5 MRP (200-220 kcal per product) + 1 salad (20 kcal per portion) + water/unsweetened tea.
  2. Active stage (14-21 weeks) 1100-1200 kcal/day 3 MRP (200-220 kcal per meal) + 2 regular meals (200-280 kcal) + water/unsweetened tea.
  3. Maintenance stage (21-28 weeks): 1200-1500 kcal/day 2 MRP (200-220 kcal per meal) + 3 regular meals (260-350 kcal) + water/unsweetened tea
  4. Stable stage (28-40 weeks): 1500-2000 kcal 1 MRP (200-220 kcal per meal) + 4 regular meals (approx. 320-450 kcal) + water/unsweetened tea Usual meals can also contain snacks with lower energy values, but it is important to consume approx. 1300-1800 kcal per day with usual foods.
02

Conditions studied

  • Overweight and Obesity
  • Body Weight

Keywords

  • nutrition
  • overweight
  • obesity
  • diet
03

In context

Overweight

3,670 studies on the registry are indexed under Overweight; 850 are open to participants now.

This study's planned enrollment of 36 is below the median of 73 across 3,175 interventional studies indexed under Overweight.

Browse Overweight studies →

Lead sponsor

Children's Hospital Srebrnjak is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • adults aged 18-60
  • both sexes
  • BMI >27 kg/m2
  • signed informed consent

Exclusion criteria

Exclusion Criteria:

  • significant comorbidities: uncontrolled diabetes mellitus requiring insulin therapy and other endocrine disorders, cardiovascular disorders and other chronic diseases (including malignancies), chronic inflammatory diseases of the gastrointestinal tract, mental disorder
  • people who are currently on or have recently went through an weight loss program (in the past 3 months)
  • people who in the past 6 months had an unwanted and uncontrolled loss of body weight >5%
  • people who underwent bariatric surgery in the past 6 months.
  • people using drugs that increase or decrease appetite
  • permanent therapy with steroid drugs, antidepressants, cytostatics, hormone therapy, beta blockers, etc.
  • people with eating disorders (bulimia)
  • alcohol and drug addicts
  • pregnancy, breastfeeding
  • unstable thyroid disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Active group

    Participants use the innovative line of products intended for body weight reduction, that represent a meal replacement for weight management

    Dietary Supplement: meal replacement product- STANDARD PRODUCT

  • Active comparator
    Active control

    Participants use the standard line of products intended for weight reduction that represent a meal replacement for weight management with already proven clinical effectiveness (positive control).

    Dietary Supplement: Meal replacement product- INNOVATIVE PRODUCT

  • No intervention
    Control group

    Participants receive personalized advice on proper nutrition for a reduction diet in which they use common food.

Interventions

  • Dietary supplementmeal replacement product- STANDARD PRODUCT

    standard product line contains common ingredients and this type of product already exists on world markets

  • Dietary supplementMeal replacement product- INNOVATIVE PRODUCT

    innovative product line contains raw materials that are considered better sources of potentially bioactive components

06

What researchers measure

Primary outcomes

  1. BM/FM

    To determine the effectiveness of a weight change diet program based on an innovative and standard product line through actual reduction of the body mass (BM) / fat mass (FM) of the participants in relation to their pre - trial body mass(BM)/fat mass (FM).

    Time frame: After 40 weeks

Secondary outcomes

  1. Anthropometric measurements

    Change in anthropometric measurements- waist and hip circumference and waist/hip ratio and waist/height ratio Measurements of participants' waist, hip and height in meters will be taken. This multiple measurements will be aggregated and presented in ratio waist \[meter\] / hip \[meter\] and ratio waist \[meter\] / height \[meter\]

    Time frame: measurements at each examination - every 2 weeks up to week 21 and every 4 weeks from week 21 to week 40

  2. Lipid profile (triglycerides, total cholesterol, HDL, LDL)

    Change of the cholesterol test/lipid panel/lipid profile (change in HDL/LDL ratio) compared to initial values

    Time frame: at the beginning of the study and after 3, 6 and 9 months

  3. Questionnaire on quality of life

    The questionnaire consists of descriptive system and visual analogue scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The visual analogue scale records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The questionnaire is in Croatian language, with a valid and accurate translation of the corresponding original document.

    Time frame: at the beginning of the study (1st week) and at the end (40th week)

07

Study locations

1 of 1 sites recruiting
  • Children's Hospital Srebrnjak
    Zagreb, 10000, Croatia
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05733871
Lead sponsor
Children's Hospital Srebrnjak
Collaborators
Belupo, Podravka d.d.
Responsible party
Mirjana Turkalj, MD (Professor, MD, PhD, Children's Hospital Srebrnjak) — Principal investigator
First posted
Feb 17, 2023
Start date
Jan 17, 2023
Primary completion
Sep 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Feb 17, 2023

Study contacts

Mirjana Turkalj, Prof., MD
Contact
mturkalj@bolnica-srebrnjak.hr
+38516391164

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion